1. Dual organ or kidney after another solid organ transplant

2. Presence of a preexisting significant GI condition that does not have a presumed causal relationship with MPA

3. Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA

4. Estimated glomerular filtration rate (eGFR) \<40 ml/min at time of possible conversion

5. Proteinuria \>1 gram/day at time of possible conversion

6. Profound bone marrow suppression at the time of possible conversion as defined as:

* Hemoglobin \<10 g/dL

* White blood cell (WBC) \< 3 K/cumm

* Platelets \<100 K/cumm

7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound infection, incisional hernia, lymphocele, seroma)

8. Elevated total cholesterol (\>350 mg/dL) and/or triglycerides (\>500 ng/dL) at time of possible conversion

9. Hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation